Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.

Santoro M, Maetzler W, Stathakos P, Martin HL, Hobert MA, Rattay TW, Gasser T, Forrester JV, Berg D, Tracey KJ, Riedel G, Teismann P.

Neurobiol Dis. 2016 Jul;91:59-68. doi: 10.1016/j.nbd.2016.02.018. Epub 2016 Feb 24.

2.

The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease.

Mustafa S, Martin HL, Burkly L, Costa A, Martins ML, Schwaninger M, Teismann P.

Neuroscience. 2016 Apr 5;319:116-22. doi: 10.1016/j.neuroscience.2016.01.034. Epub 2016 Jan 22.

3.

Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.

Martin HL, Santoro M, Mustafa S, Riedel G, Forrester JV, Teismann P.

Glia. 2016 Mar;64(3):386-95. doi: 10.1002/glia.22935. Epub 2015 Oct 29.

4.

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Mounsey RB, Mustafa S, Robinson L, Ross RA, Riedel G, Pertwee RG, Teismann P.

Exp Neurol. 2015 Nov;273:36-44. doi: 10.1016/j.expneurol.2015.07.024. Epub 2015 Aug 2.

5.

S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal Inflammation.

Niven J, Hoare J, McGowan D, Devarajan G, Itohara S, Gannagé M, Teismann P, Crane I.

PLoS One. 2015 Jul 23;10(7):e0132688. doi: 10.1371/journal.pone.0132688. eCollection 2015.

6.

The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease.

Mounsey RB, Martin HL, Nelson MC, Evans RM, Teismann P.

Neuroscience. 2015 Aug 6;300:576-84. doi: 10.1016/j.neuroscience.2015.05.048. Epub 2015 May 29.

7.

Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.

Menzfeld C, John M, van Rossum D, Regen T, Scheffel J, Janova H, Götz A, Ribes S, Nau R, Borisch A, Boutin P, Neumann K, Bremes V, Wienands J, Reichardt HM, Lühder F, Tischner D, Waetzig V, Herdegen T, Teismann P, Greig I, Müller M, Pukrop T, Mildner A, Kettenmann H, Brück W, Prinz M, Rotshenker S, Weber MS, Hanisch UK.

Glia. 2015 Jun;63(6):1083-99. doi: 10.1002/glia.22803. Epub 2015 Mar 2.

PMID:
25731696
8.

[Myeloperoxidase in the neurodegenerative process of Parkinson's disease].

Teismann P.

Dtsch Med Wochenschr. 2014 Jan;139(3):99-102. doi: 10.1055/s-0033-1359907. Epub 2013 Nov 25. Review. German.

PMID:
24277448
9.

Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.

Perier C, Bender A, García-Arumí E, Melià MJ, Bové J, Laub C, Klopstock T, Elstner M, Mounsey RB, Teismann P, Prolla T, Andreu AL, Vila M.

Brain. 2013 Aug;136(Pt 8):2369-78. doi: 10.1093/brain/awt196.

PMID:
23884809
10.

A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Martin HL, Mounsey RB, Sathe K, Mustafa S, Nelson MC, Evans RM, Teismann P.

Neuroscience. 2013 Jun 14;240:191-203. doi: 10.1016/j.neuroscience.2013.02.058. Epub 2013 Mar 7.

11.

A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats.

Nuber S, Harmuth F, Kohl Z, Adame A, Trejo M, Schönig K, Zimmermann F, Bauer C, Casadei N, Giel C, Calaminus C, Pichler BJ, Jensen PH, Müller CP, Amato D, Kornhuber J, Teismann P, Yamakado H, Takahashi R, Winkler J, Masliah E, Riess O.

Brain. 2013 Feb;136(Pt 2):412-32. doi: 10.1093/brain/aws358.

12.

S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.

Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P.

Brain. 2012 Nov;135(Pt 11):3336-47. doi: 10.1093/brain/aws250.

13.

COX-2 in the neurodegenerative process of Parkinson's disease.

Teismann P.

Biofactors. 2012 Nov-Dec;38(6):395-7. doi: 10.1002/biof.1035. Epub 2012 Jul 23. Review.

14.

Chelators in the treatment of iron accumulation in Parkinson's disease.

Mounsey RB, Teismann P.

Int J Cell Biol. 2012;2012:983245. doi: 10.1155/2012/983245. Epub 2012 Jun 13.

15.

Automated behavioral phenotyping reveals presymptomatic alterations in a SCA3 genetrap mouse model.

Hübener J, Casadei N, Teismann P, Seeliger MW, Björkqvist M, von Hörsten S, Riess O, Nguyen HP.

J Genet Genomics. 2012 Jun 20;39(6):287-99. doi: 10.1016/j.jgg.2012.04.009. Epub 2012 May 15.

PMID:
22749017
16.

Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease.

Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P.

Exp Neurol. 2012 Jun;235(2):528-38. doi: 10.1016/j.expneurol.2012.02.017. Epub 2012 Mar 7.

17.

Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity.

Teismann P, Sathe K, Bierhaus A, Leng L, Martin HL, Bucala R, Weigle B, Nawroth PP, Schulz JB.

Neurobiol Aging. 2012 Oct;33(10):2478-90. doi: 10.1016/j.neurobiolaging.2011.12.006. Epub 2012 Jan 9.

18.

Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages.

Nuber S, Petrasch-Parwez E, Arias-Carrión O, Koch L, Kohl Z, Schneider J, Calaminus C, Dermietzel R, Samarina A, Boy J, Nguyen HP, Teismann P, Velavan TP, Kahle PJ, von Hörsten S, Fendt M, Krüger R, Riess O.

Neurobiol Dis. 2011 Nov;44(2):192-204. doi: 10.1016/j.nbd.2011.06.017. Epub 2011 Jul 5.

PMID:
21767644
19.

MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.

Hsieh YC, Mounsey RB, Teismann P.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Aug;384(2):157-67. doi: 10.1007/s00210-011-0660-8. Epub 2011 Jun 12.

20.

Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.

Mounsey RB, Teismann P.

Parkinsons Dis. 2010 Dec 26;2011:617472. doi: 10.4061/2011/617472.

Supplemental Content

Loading ...
Support Center